Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2021-04-27 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2021-04-26 | Committee | Referred to the Subcommittee on Social Security. | House committee actions |
| 2021-04-26 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2021-04-26 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
| 2021-04-26 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
| 2021-04-26 | IntroReferral | Introduced in House | Library of Congress |